Stellar Pharmaceuticals Inc.
TSX VENTURE : SLX
OTC Bulletin Board : SLXCF

Stellar Pharmaceuticals Inc.

December 27, 2006 08:00 ET

Stellar Pharmaceuticals Retains Investor Relations Firm

LONDON, ONTARIO--(CCNMatthews - Dec. 27, 2006) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company")(TSX VENTURE:SLX)(OTCBB:SLXCF) is pleased to announce that it has entered into an investor relations agreement (the "Agreement") with Seventh Circle Consulting, LLC ("Seventh Circle") pursuant to which the Company will engage Seventh Circle to provide certain investor relations services for an initial period of two months.

Pursuant to the Agreement, Seventh Circle will receive a monthly fee of US$6,000.00. The Company will also reimburse Seventh Circle for any reasonable expenses incurred by them in providing the services to a maximum of US$8,000. Other than the provision of services pursuant to the Agreement, Seventh Circle has no direct or indirect interest in the Company or its securities or any right to acquire an interest in the Company.

Seventh Circle is based in New York City and is incorporated in the State of New York. Seventh Circle Consulting performs Investor Relations and Investment Banking Consulting Services to publicly traded micro-cap companies. Management has over 15 years of Wall Street experience with the last 4 years focusing on Investor Relations services to the micro-cap investor community.

Seventh Circle will be charged with raising investor awareness of the Company as well as identifying potential companies with which Stellar may pursue accretive transactions.

Shares Issued to Consultants

The Company has also announced today that it has entered into consulting agreements with Dr. David G. Stevens and Dr. Anthony D. Chris, to provide their expertise concerning orthopaedic matters which impact the Company's orthopaedic line of products and services, within the Canadian market. Pursuant to the agreement the Company will issue Dr. Stevens 2,500 common shares in the capital of the Company and Dr. Chris 1,000 shares in the capital of the Company.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Stellar Pharmaceuticals Inc.
    Peter Riehl
    President & CEO
    (519) 434-1540 or Toll Free 1-800-639-0643
    or
    Stellar Pharmaceuticals Inc.
    Arnold Tenney
    Cell (416) 587-3200
    or
    Seventh Circle Consulting LLC
    INVESTOR RELATIONS COUNSEL
    Christine Petraglia
    (212) 878-6500
    Email: christine@seventhcirclellc.com